OHB SE stock slid 6.3% on Monday following a formal decision by the company’s management board to fix the terms of its equity raise. Management approved a subscription price of €300 per new share for as many as 1,702,480 shares, a package intended to generate gross proceeds of up to approximately €510.7 million.
The announcement settled a significant point of uncertainty that had affected trading since the company revealed on June 15 that it planned to raise around €500 million via a rights offering without setting a price. Investors had been valuing the shares with the prospect of heavy dilution in mind while the pricing and structure remained unknown.
Under the approved plan, the Fuchs family and KKR-affiliated Orchid Lux HoldCo have waived their subscription rights. As a result, about 94% of the new shares will be channeled to qualified institutional investors through a private placement, and KKR intends to sell a portion of its roughly 29% stake concurrently with the capital raise.
The combined transactions are expected to lift OHB’s free float from roughly 6% to about 26%, a change analysts have described as structurally beneficial for the stock’s liquidity and its accessibility to institutional buyers over the longer term.
Despite that potential structural improvement, the share price remains a long way from its 52-week high of €685. At the same time, the stock has recovered materially from its 52-week low of €63.6. Market commentary around the move highlights the tension between OHB’s operational strength and the immediate dilution effects of the financing.
Operationally, OHB carries a record order backlog of approximately €3.4 billion, a metric cited alongside the capital plan to characterise the company’s business momentum. However, the near-term mechanics of the equity raise and the accompanying placement and stake sale have dominated investor attention in the trading response.
No new financial figures beyond the approved subscription price, share count and estimated proceeds were disclosed in the board announcement. The decision nonetheless resolves the main outstanding variable that had been influencing market pricing since the June 15 disclosure of the intended rights offering.